Elliot Hershberg

1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

Elliot Hershberg analyzes structural challenges in modern biotechnology and drug development. He focuses on the economic factors driving approval costs up to $2.5 billion per therapeutic.

12statements → 7claims → 6claims resolved → 67%fully supported → 3.92/5average certainty → 2.17/5average debate potential →

4 supported 2 partly supported 0 contradicted 1 not yet assessed how the 7 claims stand · each chip opens the sources

7 assertions · 3 opinions · 1 insight · 1 disclosure · every statement was checked. The predictions and assertions are the 7 claims: statements the public record can support or contradict. 6 are resolved, 1 is not yet assessed. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Elliot argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Hershberg: Biotech startups generate two-thirds of newly approved drugs
“Biotech startups now make two thirds of the drugs that go to market.”
Elliot Hershberg Nov 14, 2025 ▶ 15:01 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

How they sound: speaking style how? →

250 words/min while actually speaking · 44 um and uh per 1k words

No argument clarity score for Elliot Hershberg: no usable question→answer exchanges on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews.

Measured by listening to the audio itself: 4,384 words across 1 episode of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Elliot Hershberg said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Opinion
Hershberg: Restricting US-China biotech transactions via BIOSECURE Act is net negative
“I do think that there's some nuance in terms of how we think about regulation for this, right? It's probably not biosecure where you are totally trying to restrict Relationships and transactions between the U S and China, because that's just sort of net negati…”
Elliot Hershberg Nov 14, 2025 ▶ 21:07 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Disclosure
Hershberg: Zero Amplify portfolio companies are running first-in-human trials in US
“So we have three companies in the next 12 to 18 months that will be starting first in human trials. You know, guess how many are actually doing their first studies in the United States?”
Elliot Hershberg Nov 14, 2025 ▶ 8:28 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Partly supported
Hershberg: Clinical trial costs per patient ballooned from $10,000 to $500,000
“So when George Yonkopoulos started Regeneron, it cost about 10,000 dollars per patient in trial. That's ballooned to 500,000 dollars.”
Elliot Hershberg Nov 14, 2025 ▶ 45:06 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Not yet assessed · timeframe Nov 2025
Hershberg: Clinical research market consolidated into 12 primary providers
“So it actually turns out that there's been this enormous consolidation of the clinical research organization market that's come down to about a dozen providers who have each done roughly 40 acquisitions across 30 years.”
Elliot Hershberg Nov 14, 2025 ▶ 9:23 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Supported
Hershberg: Biotech startups generate two-thirds of newly approved drugs
“Biotech startups now make two thirds of the drugs that go to market.”
Elliot Hershberg Nov 14, 2025 ▶ 15:01 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Opinion
Hershberg: AI biology platforms where the platform is the product remain compelling
“This is where I'm sort of an unequivocal platform bull still is that I think like one of the most exciting opportunities for AI and biology is this sort of world that we're going to where the platform is the product, right?”
Elliot Hershberg Nov 14, 2025 ▶ 32:31 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Supported
Hershberg: Public biotech market contains an enormous amount of EV-negative companies
“We have an enormous amount of EV negative public companies.”
Elliot Hershberg Nov 14, 2025 ▶ 0:48 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Insight
Hershberg: Drug development alpha relies on proprietary datasets and modeling tools
“To actually make something more beautiful and more potent at this stage of the game, the alpha probably is in really interesting data sets, new modeling tools and capabilities.”
Elliot Hershberg Nov 14, 2025 ▶ 28:07 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Opinion
Hershberg: Re-bundling biotech tools into integrated platforms is the primary opportunity
“I think that in biotech, we're in this sort of moment where there's a lot of opportunity in re-bundling. The types of platforms that I see that I'm super excited about Are this composite of incredible synthetic biology and genomics tools plus modeling you know…”
Elliot Hershberg Nov 14, 2025 ▶ 57:26 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Supported
Hershberg: Certain funded AI biology firms do not plan to develop drugs
“There's a lot of AI and biology companies that are raising a lot of capital and some just have no aims to make drugs.”
Elliot Hershberg Nov 14, 2025 ▶ 59:00 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Partly supported
Hershberg: Biotech experienced a 7-8 month IPO drought
“There was a stretch of seven to eight months where there were no biotech IPOs”
Elliot Hershberg Nov 14, 2025 ▶ 0:51 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Assertion Supported
Hershberg: Illumina grew next-generation sequencing sales from zero to over $10B
“So at one point Illumina sold exactly zero dot zero dollars of next generation sequencing technology to the industry, right? That turned into over ten billion dollars of sales and, you know, independent large listed companies where their cost of goods sold wer…”
Elliot Hershberg Nov 14, 2025 ▶ 59:28 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Appearances (1)

EpisodeDateSpeaking time
The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation Nov 14, 2025 22m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.